Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405722 | 1.00 | ALDH1A1 (0.38) | ALDH1A1RAB9AKDM1ACXCR3HDAC4 | |
| SCHEMBL516345 | 0.97 | ALDH1A1 (0.39) | ALDH1A1RAB9AKDM1AHDAC4HDAC2 | |
| SCHEMBL516332 | 0.88 | ALDH1A1 (0.32) | ALDH1A1RAB9AHDAC4HDAC2HDAC8 | |
| SCHEMBL3478278 | 0.79 | ALDH1A1 (0.40) | ALDH1A1RAB9AKDM1ACXCR3HDAC4 | |
| SCHEMBL3966810 | 0.79 | ALDH1A1 (0.40) | ALDH1A1RAB9AKDM1ACXCR3HDAC4 | |
| SCHEMBL15457506 | 0.79 | ALDH1A1 (0.40) | ALDH1A1RAB9AKDM1ACXCR3HDAC4 | |
| SCHEMBL517221 | 0.76 | — | — | |
| SCHEMBL7776734 | 0.76 | ALDH1A1 (0.41) | ALDH1A1RAB9AKDM1ACXCR3HDAC4 | |
| SCHEMBL31671011 | 0.75 | ALDH1A1 (0.41) | ALDH1A1RAB9ACXCR3HDAC4HDAC2 | |
| SCHEMBL3965255 | 0.74 | ALDH1A1 (0.44) | ALDH1A1RAB9ACXCR3ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334107-B1 | NON-METALLOCENE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME FOR THE POLYMERISATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-6872843-B2 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerization of olefins | BASELL POLYOLEFINE GMBH (DE) | 2005-03-29 | — | — | US | disclosed |
| US-20040023940-A1 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerisation of olefins | EQUISTAR CHEMICALS, LP | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023940-A1 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerisation of olefins | SOAT2, NOTUM, SOAT1 | ALDH1A1 1428/4885RAB9A 4353/4885KDM1A 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.